Drug details

Eticovo (etanercept injection)

type of DMARDs, TNF Inhibitors, Antipsoriatics, Systemic

Eticovo (etanercept-ykro) is a tumor necrosis factor (TNF) blocker indicated for the treatment of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA) in patients aged 2 years or older, psoriatic arthritis (PsA), ankylosing spondylitis (AS), and plaque psoriasis (PsO) in patients 4 years or older. Eticovo is biosimilar to Enbrel (etanercept).

The drug is often used to treat Ankylosing spondylitis , Arthritis , Psoriatic arthritis .

This drug may have the following side effects:

• itching,
• rash,
• diarrhea,
• fever, and
• hives
• injection site reactions,
• infections (such as upper respiratory infections, nasopharyngitis, sinusitis, and influenza),

The following drugs are related to Eticovo, either as a replacement or used together:

• Orencia (abatacept)
• Cibinqo (abrocitinib tablets)
• Actemra (tocilizumab injection)
• Humira (adalimumab injection solution for subcutaneous administration)
• Arava (leflunomide)
• Azulfidine EN-Tabs (sulfasalazine delayed release tablets)
• Cimzia (certolizumab pegol injection)
• Enbrel (etanercept)
• Simponi Aria (golimumab for infusion)
• Simponi Injection (golimumab injection)
• Remicade (infliximab)
• Trexall (methotrexate)
• Rinvoq (upadacitinib extended-release tablets)
• Rituxan (rituximab)
• Rituxan Hycela (rituximab and hyaluronidase human injection)